- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03391739
CART-19 Cells For R/R B-ALL (CCFRRBA)
December 30, 2017 updated by: Jianda Hu, Fujian Medical University
CART-19 Cells For Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL).
However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL).
This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
20
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Recruiting
- Fujian Medical University Union Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 60 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed written informed consent
- Aged between 1-60 years
- Patients with relapsed/refractory B-cell ALL
- Cardiac: Left ventricular ejection fraction ≥ 50%
- Adequate renal and hepatic function
- Performance status: Karnofsky ≥ 70%
Exclusion Criteria:
- Pregnant or lactating females.
- Any co-morbidity precluding the administration of CART-19 cells.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
CART-19 cells treat
|
CART-19 cells treat
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Leukemia free survival
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events that are related to treatment
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2016
Primary Completion (Anticipated)
December 1, 2019
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
December 30, 2017
First Submitted That Met QC Criteria
December 30, 2017
First Posted (Actual)
January 5, 2018
Study Record Updates
Last Update Posted (Actual)
January 5, 2018
Last Update Submitted That Met QC Criteria
December 30, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- CART-19-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory B-cell ALL
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory B-Cell MalignanciesChina, Australia
-
Minghui Pharmaceutical (Shanghai) LTDRecruitingRelapsed/Refractory B-cell MalignanciesChina
-
Gilead SciencesCompletedRelapsed/Refractory B-cell MalignanciesFrance, United Kingdom
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
National Taiwan University HospitalNot yet recruitingRelapsed/Refractory B-Cell Malignancies
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalNot yet recruitingCD19-positive Relapsed or Refractory B-cell MalignanciesChina
-
EdiGene (GuangZhou) Inc.The First Affiliated Hospital of Henan University of Science and TechnologyActive, not recruitingRelapsed or Refractory B-cell Malignancy(NHL/ALL)China
-
Curis, Inc.The Leukemia and Lymphoma SocietyCompletedLymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditionsUnited States
-
Prelude TherapeuticsCompletedAdenoid Cystic Carcinoma | Refractory Chronic Myelomonocytic Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Advanced Solid Tumors | Relapsed/Refractory Myelodysplasia | Relapsed...United States
-
Nantes University HospitalWithdrawnCD22+ Relapsed/Refractory B-ALLFrance
Clinical Trials on CART-19 cells
-
Fujian Medical UniversityUnknown
-
University of PennsylvaniaTerminated
-
The Affiliated Hospital of the Chinese Academy...UnknownLeukemia, Lymphocytic, AcuteChina
-
Shanghai Unicar-Therapy Bio-medicine Technology...RecruitingAcute Myeloid LeukemiaChina
-
University of PennsylvaniaTerminatedLYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)United States
-
Fujian Medical UniversityUnknown
-
University of PennsylvaniaCompletedPatients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment OptionsUnited States
-
University of PennsylvaniaCompletedRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditionsUnited States
-
University of PennsylvaniaTerminated